Kestra Medical Technologies Partners with Biobeat to Enhance ASSURE Wearable Defibrillator Diagnostics
Kestra Medical Technologies announced a strategic collaboration with Biobeat Technologies to expand diagnostic insight for patients prescribed the ASSURE Wearable Cardioverter Defibrillator. The agreement is anchored by an exclusive license and co-development arrangement and includes a $5M equity investment in Biobeat's recently announced Series B financing. Biobeat has developed the only clinically validated, FDA-cleared cuffless, patch-worn ambulatory blood pressure monitoring device, leveraging photoplethysmography-based sensing to deliver continuous, noninvasive blood pressure measurement over a 24-hour period for hypertension diagnosis and management in the outpatient cardiac recovery setting. Kestra intends to integrate Biobeat's technology into its product portfolio to make ABPM data available for patients prescribed the ASSURE WCD.
Trade with 70% Backtested Accuracy
Analyst Views on KMTS
About KMTS
About the author
Kestra Medical Technologies Partners with Biobeat for $5 Million Investment to Enhance Cardiac Recovery Monitoring
- Strategic Collaboration: Kestra Medical Technologies has entered into a strategic collaboration with Biobeat Technologies, involving a $5 million equity investment aimed at integrating Biobeat's cuffless blood pressure monitoring technology into the ASSURE® Wearable Cardioverter Defibrillator, thereby enhancing patient monitoring capabilities and clinical decision support.
- Technological Integration Benefits: Biobeat's FDA-cleared cuffless blood pressure monitoring device provides continuous 24-hour blood pressure data, which will enable Kestra to offer more comprehensive health monitoring for patients during cardiac recovery, particularly in managing hypertensive patients.
- Clinical Research Support: The recent clinical evaluation study of the ASSURE wearable cardioverter defibrillator by Kestra revealed that 72% of participants were hypertensive, underscoring the importance of blood pressure monitoring during cardiac recovery and providing stronger evidence for clinical decision-making.
- Market Outlook: This collaboration not only enhances Kestra's competitiveness in cardiac health monitoring but also demonstrates its strategic vision in promoting at-home patient care and optimizing medical decision-making, which is expected to attract more attention from healthcare providers.
Kestra Medical Technologies to Present at J.P. Morgan Healthcare Conference on January 13
- Conference Schedule: Kestra Medical Technologies is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 2:15 p.m. Pacific Time, showcasing its latest advancements in wearable medical devices, which is expected to attract investor and industry attention.
- Investor Relations: Interested parties can access the live webcast and replay of the presentation by visiting Kestra Medical Technologies' investor relations website, which will help enhance the company's visibility and transparency among investors.
- Company Background: Kestra Medical Technologies focuses on transforming patient outcomes in cardiovascular disease through intuitive, intelligent, and connected monitoring and therapeutic intervention technologies, demonstrating its innovative potential in the digital healthcare sector.
- Market Positioning: As a commercial-stage wearable medical device company, Kestra's technology aims to improve patient health outcomes, indicating its strategic significance in the rapidly evolving digital healthcare market.
Kestra Medical Technologies to Present at J.P. Morgan Healthcare Conference on January 13
- Conference Schedule: Kestra Medical Technologies is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 at 2:15 p.m. Pacific Time, showcasing its latest advancements in wearable medical devices, which is expected to attract investor and industry attention.
- Company Background: Focused on transforming patient outcomes in cardiovascular disease, Kestra employs intuitive, intelligent, and connected monitoring and therapeutic intervention technologies, highlighting its innovative capabilities and market potential in the digital healthcare sector.
- Investor Relations: Interested parties can access the live webcast and replay of the presentation by visiting Kestra's investor relations website, enhancing engagement and transparency with investors.
- Industry Impact: This conference provides Kestra with a platform to showcase its technologies and market strategies, potentially fostering further development in the medical device industry and boosting investor confidence.
Kestra Medical Reports 53% Increase in Q2 Revenue and Raises FY26 Revenue Forecast Once More
Financial Performance: Kestra Medical Technologies reported a 53% increase in revenue for Q2 fiscal 2026, reaching $22.6 million, while gross profit also rose significantly to $11.4 million, leading to an expanded gross margin of 50.6%.
Operating Expenses and Losses: The company faced wider GAAP net losses of $32.8 million, up from $20.6 million in the previous year, with operating expenses increasing to $43.2 million, including non-recurring costs.
Cash Position: As of October 31, 2025, Kestra had $175 million in cash and cash equivalents, not accounting for an additional $148 million from a public offering that closed on December 4, 2025.
Revenue Guidance: Kestra has raised its revenue guidance for fiscal 2026 to $91 million, marking a 52% increase over the previous year's revenue of $59.8 million, following multiple revisions from an initial estimate of $85 million.
Kestra Medical to Report Q2 Fiscal 2026 Results on December 11
- Earnings Announcement: Kestra Medical Technologies will report its Q2 fiscal 2026 financial results on December 11, with a corresponding conference call scheduled for 4:30 PM Eastern Time, aimed at updating investors on financial performance and business developments.
- Investor Engagement: The company encourages participants to register 10 minutes prior to the call, ensuring smooth participation and demonstrating its commitment to investor communication.
- Technological Focus: Kestra Medical is dedicated to transforming patient outcomes in cardiovascular disease through intuitive, intelligent, and connected monitoring and therapeutic intervention technologies, highlighting its innovative potential in the digital healthcare sector.
- Market Positioning: As a commercial-stage wearable medical device company, Kestra Medical aims to enhance treatment outcomes for cardiovascular patients, reflecting its strategic positioning in the rapidly evolving digital healthcare market.
Kestra Increases Price of Primary Public Offering of Common Shares to $23 Each
Public Offering Details: Kestra Medical Technologies has announced a public offering of 6 million common shares priced at $23.00 each, expected to close around December 4, 2025, with gross proceeds estimated at $138 million.
Use of Proceeds: The net proceeds from the offering will be allocated to advancing wearable medical devices, expanding commercialization, investing in technology development, and supporting working capital.
Financial Performance: Preliminary results for Q2 of fiscal 2026 indicate expected revenue between $22.2 million and $22.6 million, a 52% increase from the previous year, while losses from operations are projected to rise to between $31.6 million and $32.0 million.
Stock Performance: KMTS shares closed at $23.01, down 6.80%, but saw a slight increase to $23.05 in after-hours trading, with a trading volume of approximately 459,000 shares compared to an average of 272,000 shares.
Kestra Medical Technologies Partners with Biobeat for $5 Million Investment to Enhance Cardiac Recovery Monitoring
- Strategic Collaboration: Kestra Medical Technologies has entered into a strategic collaboration with Biobeat Technologies, involving a $5 million equity investment aimed at integrating Biobeat's cuffless blood pressure monitoring technology into the ASSURE® Wearable Cardioverter Defibrillator, thereby enhancing patient monitoring capabilities and clinical decision support.
- Technological Integration Benefits: Biobeat's FDA-cleared cuffless blood pressure monitoring device provides continuous 24-hour blood pressure data, which will enable Kestra to offer more comprehensive health monitoring for patients during cardiac recovery, particularly in managing hypertensive patients.
- Clinical Research Support: The recent clinical evaluation study of the ASSURE wearable cardioverter defibrillator by Kestra revealed that 72% of participants were hypertensive, underscoring the importance of blood pressure monitoring during cardiac recovery and providing stronger evidence for clinical decision-making.
- Market Outlook: This collaboration not only enhances Kestra's competitiveness in cardiac health monitoring but also demonstrates its strategic vision in promoting at-home patient care and optimizing medical decision-making, which is expected to attract more attention from healthcare providers.
Kestra Medical Technologies to Present at J.P. Morgan Healthcare Conference on January 13
- Conference Schedule: Kestra Medical Technologies is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 2:15 p.m. Pacific Time, showcasing its latest advancements in wearable medical devices, which is expected to attract investor and industry attention.
- Investor Relations: Interested parties can access the live webcast and replay of the presentation by visiting Kestra Medical Technologies' investor relations website, which will help enhance the company's visibility and transparency among investors.
- Company Background: Kestra Medical Technologies focuses on transforming patient outcomes in cardiovascular disease through intuitive, intelligent, and connected monitoring and therapeutic intervention technologies, demonstrating its innovative potential in the digital healthcare sector.
- Market Positioning: As a commercial-stage wearable medical device company, Kestra's technology aims to improve patient health outcomes, indicating its strategic significance in the rapidly evolving digital healthcare market.
Kestra Medical Technologies to Present at J.P. Morgan Healthcare Conference on January 13
- Conference Schedule: Kestra Medical Technologies is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 at 2:15 p.m. Pacific Time, showcasing its latest advancements in wearable medical devices, which is expected to attract investor and industry attention.
- Company Background: Focused on transforming patient outcomes in cardiovascular disease, Kestra employs intuitive, intelligent, and connected monitoring and therapeutic intervention technologies, highlighting its innovative capabilities and market potential in the digital healthcare sector.
- Investor Relations: Interested parties can access the live webcast and replay of the presentation by visiting Kestra's investor relations website, enhancing engagement and transparency with investors.
- Industry Impact: This conference provides Kestra with a platform to showcase its technologies and market strategies, potentially fostering further development in the medical device industry and boosting investor confidence.
Kestra Medical Reports 53% Increase in Q2 Revenue and Raises FY26 Revenue Forecast Once More
Financial Performance: Kestra Medical Technologies reported a 53% increase in revenue for Q2 fiscal 2026, reaching $22.6 million, while gross profit also rose significantly to $11.4 million, leading to an expanded gross margin of 50.6%.
Operating Expenses and Losses: The company faced wider GAAP net losses of $32.8 million, up from $20.6 million in the previous year, with operating expenses increasing to $43.2 million, including non-recurring costs.
Cash Position: As of October 31, 2025, Kestra had $175 million in cash and cash equivalents, not accounting for an additional $148 million from a public offering that closed on December 4, 2025.
Revenue Guidance: Kestra has raised its revenue guidance for fiscal 2026 to $91 million, marking a 52% increase over the previous year's revenue of $59.8 million, following multiple revisions from an initial estimate of $85 million.
Kestra Medical to Report Q2 Fiscal 2026 Results on December 11
- Earnings Announcement: Kestra Medical Technologies will report its Q2 fiscal 2026 financial results on December 11, with a corresponding conference call scheduled for 4:30 PM Eastern Time, aimed at updating investors on financial performance and business developments.
- Investor Engagement: The company encourages participants to register 10 minutes prior to the call, ensuring smooth participation and demonstrating its commitment to investor communication.
- Technological Focus: Kestra Medical is dedicated to transforming patient outcomes in cardiovascular disease through intuitive, intelligent, and connected monitoring and therapeutic intervention technologies, highlighting its innovative potential in the digital healthcare sector.
- Market Positioning: As a commercial-stage wearable medical device company, Kestra Medical aims to enhance treatment outcomes for cardiovascular patients, reflecting its strategic positioning in the rapidly evolving digital healthcare market.
Kestra Increases Price of Primary Public Offering of Common Shares to $23 Each
Public Offering Details: Kestra Medical Technologies has announced a public offering of 6 million common shares priced at $23.00 each, expected to close around December 4, 2025, with gross proceeds estimated at $138 million.
Use of Proceeds: The net proceeds from the offering will be allocated to advancing wearable medical devices, expanding commercialization, investing in technology development, and supporting working capital.
Financial Performance: Preliminary results for Q2 of fiscal 2026 indicate expected revenue between $22.2 million and $22.6 million, a 52% increase from the previous year, while losses from operations are projected to rise to between $31.6 million and $32.0 million.
Stock Performance: KMTS shares closed at $23.01, down 6.80%, but saw a slight increase to $23.05 in after-hours trading, with a trading volume of approximately 459,000 shares compared to an average of 272,000 shares.
